Alteogen is experiencing a strong rally amid expectations for additional technology exports.
As of 1:47 PM on June 24, the Korea Exchange reported that Alteogen's shares rose by 34,000 won (10.21%) to 367,000 won. At one point during the trading session, the stock climbed to 375,500 won, further increasing its gains.
The stock initially started on an upward trend but briefly turned negative early in the session. However, buying interest surged, leading to a significant rebound in share prices.
Market analysts attribute the improved investor sentiment to the potential for new technology export contracts. Alteogen is expanding its technology transfer collaborations with global pharmaceutical companies based on its proprietary human hyaluronidase technology, ALT-B4.
According to media reports, CEO Jeon Tae-yeon stated that negotiations for additional technology exports with global pharmaceutical firms have entered the final stages during the recent 2026 Bio International Convention in San Diego, USA.
Analysts believe that if these negotiations are successful, expectations for Alteogen's technological capabilities and business expansion will increase significantly. However, as the details of the contracts and specific conditions have not yet been disclosed, attention is focused on future announcements and disclosures related to this matter.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.